{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:38:09Z","timestamp":1793655489390,"version":"4.5.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":91,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-59298-w","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:39:24Z","timestamp":1782859164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Six-month statin therapy and short-term MASLD progression: a prospective cohort study adjusted for abdominal obesity and glycemic control"],"prefix":"10.1038","volume":"16","author":[{"given":"Iryna","family":"Halabitska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mykhailo","family":"Buchynskyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Kamyshna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlo","family":"Petakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleh","family":"Lushchak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksandr","family":"Kamyshnyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"1","key":"59298_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12933-022-01697-0","volume":"21","author":"XD Zhou","year":"2022","unstructured":"Zhou, X. D. et al. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc. Diabetol. 21(1), 270 (2022).","journal-title":"Cardiovasc. Diabetol."},{"issue":"2","key":"59298_CR2","doi-asserted-by":"publisher","first-page":"101281","DOI":"10.1016\/j.aohep.2023.101281","volume":"29","author":"S Hong","year":"2024","unstructured":"Hong, S. et al. From NAFLD to MASLD: When metabolic comorbidity matters. Ann. Hepatol. 29(2), 101281 (2024).","journal-title":"Ann. Hepatol."},{"key":"59298_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2147\/HMER.S506402","volume":"17","author":"AM Mostafa","year":"2025","unstructured":"Mostafa, A. M. et al. MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk. Hepatic Med.: Evid. Res. 17, 75\u201390 (2025).","journal-title":"Hepatic Med.: Evid. Res."},{"issue":"16","key":"59298_CR4","doi-asserted-by":"publisher","first-page":"8081","DOI":"10.3390\/ijms26168081","volume":"26","author":"G Gallo","year":"2025","unstructured":"Gallo, G., Nalli, G., Baratta, F., Desideri, G. & Savoia, C. Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention. Int. J. Mol. Sci. 26(16), 8081 (2025).","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"59298_CR5","doi-asserted-by":"publisher","first-page":"101511","DOI":"10.1016\/j.aohep.2024.101511","volume":"29","author":"L Vega","year":"2024","unstructured":"Vega, L. et al. Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis. Ann. Hepatol. 29(4), 101511 (2024).","journal-title":"Ann. Hepatol."},{"issue":"1","key":"59298_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5009\/gnl250275","volume":"20","author":"J Yang","year":"2026","unstructured":"Yang, J. et al. Mortality and Cardiovascular Outcomes in Patients with MAFLD Compared with Patients with MASLD: A Systematic Review and Meta-Analysis. Gut and liver. 20(1), 137\u2013152 (2026).","journal-title":"Gut and liver."},{"issue":"3","key":"59298_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/medicina61030387","volume":"61","author":"A Pezzoli","year":"2025","unstructured":"Pezzoli, A. et al. The Management of Cardiometabolic Risk in MAFLD: Therapeutic Strategies to Modulate Deranged Metabolism and Cholesterol Levels. Medicina (Kaunas) 61(3), 387 (2025).","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"59298_CR8","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/biom15030324","volume":"15","author":"M Zisis","year":"2025","unstructured":"Zisis, M. et al. Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment. Biomolecules 15(3), 324 (2025).","journal-title":"Biomolecules"},{"key":"59298_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2022.07.004","volume":"356","author":"AC Razavi","year":"2022","unstructured":"Razavi, A. C., Mehta, A. & Sperling, L. S. Statin therapy for the primary prevention of cardiovascular disease: Pros. Atherosclerosis 356, 41\u201345 (2022).","journal-title":"Atherosclerosis"},{"issue":"4","key":"59298_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101313","volume":"7","author":"B Yun","year":"2025","unstructured":"Yun, B., Park, H., Lee, J., Kim, B. K. & Yoon, J. H. Statin use and liver-related prognosis among patients with MASLD. JHEP Rep.\u202f: Innov. Hepatol. 7(4), 101313 (2025).","journal-title":"JHEP Rep. : Innov. Hepatol."},{"issue":"1","key":"59298_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/livers5010004","volume":"5","author":"T Prasoppokakorn","year":"2025","unstructured":"Prasoppokakorn, T. Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Livers. 5(1), 4 (2025).","journal-title":"Livers."},{"issue":"1","key":"59298_CR12","first-page":"84","volume":"14","author":"I Commins","year":"2026","unstructured":"Commins, I. et al. Efficacy and Safety of Statins in MASLD and Other Chronic Liver Diseases. Med. Sci. (Basel, Switzerland). 14(1), 84 (2026).","journal-title":"Med. Sci. (Basel, Switzerland)."},{"issue":"12","key":"59298_CR13","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.3390\/nu16121925","volume":"16","author":"N Miano","year":"2024","unstructured":"Miano, N. et al. Malnutrition-Related Liver Steatosis, CONUT Score and Poor Clinical Outcomes in an Internal Medicine Department. Nutrients 16(12), 1925 (2024).","journal-title":"Nutrients"},{"key":"59298_CR14","doi-asserted-by":"publisher","first-page":"117805","DOI":"10.1016\/j.biopha.2024.117805","volume":"183","author":"ENG da Silva Pereira","year":"2025","unstructured":"da Silva Pereira, E. N. G., Franco, R. L. C., Santos, R. DCd. & Daliry, A. Statins and non-alcoholic fatty liver disease: A concise review. Biomed. Pharmacother. 183, 117805 (2025).","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"59298_CR15","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/MCG.0000000000001546","volume":"56","author":"J Singh","year":"2022","unstructured":"Singh, J. et al. Combined Use of Aspirin and Statin is Associated With a Decreased Incidence of Hepatocellular Carcinoma. J. Clin. Gastroenterol. 56(4), 369\u2013373 (2022).","journal-title":"J. Clin. Gastroenterol."},{"issue":"1","key":"59298_CR16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","volume":"70","author":"E Pose","year":"2019","unstructured":"Pose, E., Trebicka, J., Mookerjee, R. P., Angeli, P. & Gin\u00e8s, P. Statins: Old drugs as new therapy for liver diseases?. J. Hepatol. 70(1), 194\u2013202 (2019).","journal-title":"J. Hepatol."},{"issue":"4","key":"59298_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/livers5040058","volume":"5","author":"M Dallio","year":"2025","unstructured":"Dallio, M. et al. From \u201cMAFLD\u201d to \u201cMASLD\u201d: Was This Revolution Worth It? A Head-to-Head Comparison of MAFLD and MASLD Criteria in Estimating Liver Disease Progression and Cardiovascular Risk in Real Life. Livers. 5(4), 58 (2025).","journal-title":"Livers."},{"issue":"1","key":"59298_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70144","volume":"9","author":"M Gupta","year":"2026","unstructured":"Gupta, M., Lachhwani, H., Chandra, K. P., Awasthi, R. & Kumar, D. Effectiveness of Saroglitazar in MASLD Patients: A Prospective, Real-World Assessment of Liver and Metabolic Health. Endocrinol. Diabetes & Metab. 9(1), e70144 (2026).","journal-title":"Endocrinol. Diabetes & Metab."},{"key":"59298_CR19","doi-asserted-by":"publisher","first-page":"1502791","DOI":"10.3389\/fphar.2024.1502791","volume":"15","author":"B Wang","year":"2024","unstructured":"Wang, B. et al. Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System database. Front. Pharmacol. 15, 1502791 (2024).","journal-title":"Front. Pharmacol."},{"issue":"5","key":"59298_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.5694\/mja2.70008","volume":"223","author":"LA Adams","year":"2025","unstructured":"Adams, L. A. et al. Assessment of metabolic dysfunction-associated fatty liver disease in primary care: a consensus statement summary. Med. J. Aust. 223(5), 268\u2013276 (2025).","journal-title":"Med. J. Aust."},{"issue":"1","key":"59298_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s44355-025-00030-2","volume":"2","author":"MT Tantu","year":"2025","unstructured":"Tantu, M. T. et al. Pathophysiology, noninvasive diagnostics and emerging personalized treatments for metabolic associated liver diseases. npj Gut and Liver. 2(1), 18 (2025).","journal-title":"npj Gut and Liver."},{"key":"59298_CR22","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jare.2024.12.020","volume":"76","author":"W Zeng","year":"2025","unstructured":"Zeng, W. et al. Advances in statin adverse reactions and the potential mechanisms: A systematic review. J. Adv. Res. 76, 781\u2013797 (2025).","journal-title":"J. Adv. Res."},{"issue":"2","key":"59298_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/bcp.14943","volume":"88","author":"D Pastori","year":"2022","unstructured":"Pastori, D. et al. Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. Br. J. Clin. Pharmacol. 88(2), 441\u2013451 (2022).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"59298_CR24","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.3390\/molecules29081859","volume":"29","author":"S Zhang","year":"2024","unstructured":"Zhang, S., Ren, X., Zhang, B., Lan, T. & Liu, B. A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action. Molecules 29(8), 1859 (2024).","journal-title":"Molecules"},{"issue":"5","key":"59298_CR25","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas, T. et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J. Hepatol. 66(5), 1022\u20131030 (2017).","journal-title":"J. Hepatol."},{"issue":"1","key":"59298_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.55729\/2000-9666.1426","volume":"15","author":"U Dayal","year":"2025","unstructured":"Dayal, U. et al. MAFLD: Exploring the Systemic Effects Beyond Liver. J. Commun. Hospital Internal Med. Perspect. 15(1), 42\u201348 (2025).","journal-title":"J. Commun. Hospital Internal Med. Perspect."},{"issue":"6","key":"59298_CR27","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1007\/s12072-024-10731-0","volume":"18","author":"M Suoh","year":"2024","unstructured":"Suoh, M., Esmaili, S., Eslam, M. & George, J. Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research. Hep. Intl. 18(6), 1740\u20131755 (2024).","journal-title":"Hep. Intl."},{"issue":"2","key":"59298_CR28","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3390\/pharmaceutics16020214","volume":"16","author":"N Khatiwada","year":"2024","unstructured":"Khatiwada, N. & Hong, Z. Potential Benefits and Risks Associated with the Use of Statins. Pharmaceutics. 16(2), 214 (2024).","journal-title":"Pharmaceutics."},{"issue":"17","key":"59298_CR29","doi-asserted-by":"publisher","first-page":"8429","DOI":"10.3390\/ijms26178429","volume":"26","author":"S Khan","year":"2025","unstructured":"Khan, S., Huda, B., Bhurka, F., Patnaik, R. & Banerjee, Y. Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-\u03baB, NLRP3 Inflammasome, and Cytokine Regulatory Axes. Int. J. Mol. Sci. 26(17), 8429 (2025).","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"59298_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00392-025-02833-y","volume":"115","author":"PM Siegel","year":"2026","unstructured":"Siegel, P. M. et al. A practical guide to the management of dyslipidaemia. Clin. Res. Cardiol. 115(2), 185\u2013197 (2026).","journal-title":"Clin. Res. Cardiol."},{"key":"59298_CR31","doi-asserted-by":"crossref","unstructured":"Suzuki, A., Karachaliou, G. S., Perkins, A. M., Dorn, C., Reeves, RM., Arnold T, et al. Age-specific protective effects of statins against cirrhosis in patients with chronic liver enzyme elevation associated with metabolic dysfunction: a retrospective cohort study of electronic health records. eClinicalMedicine. 87 (2025).","DOI":"10.1016\/j.eclinm.2025.103431"},{"issue":"1","key":"59298_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/hep.28506","volume":"64","author":"TG Simon","year":"2016","unstructured":"Simon, T. G., Bonilla, H., Yan, P., Chung, R. T. & Butt, A. A. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatol. (Baltimore, MD) 64(1), 47\u201357 (2016).","journal-title":"Hepatol. (Baltimore, MD)"},{"issue":"1","key":"59298_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jhep.2014.08.013","volume":"62","author":"TG Simon","year":"2015","unstructured":"Simon, T. G., King, L. Y., Zheng, H. & Chung, R. T. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J. Hepatol. 62(1), 18\u201323 (2015).","journal-title":"J. Hepatol."},{"key":"59298_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100887","volume":"40","author":"B Mihaylova","year":"2024","unstructured":"Mihaylova, B. et al. Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study. Lancet Regional Health - Europe. 40, 100887 (2024).","journal-title":"Lancet Regional Health - Europe."},{"issue":"7","key":"59298_CR35","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/annrheumdis-2017-212461","volume":"77","author":"PC Taylor","year":"2018","unstructured":"Taylor, P. C. et al. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Ann. Rheum. Dis. 77(7), 988\u2013995 (2018).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"59298_CR36","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12933-021-01338-y","volume":"20","author":"ML Morieri","year":"2021","unstructured":"Morieri, M. L. et al. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets\u2019 attainment in subjects with and without type 2 diabetes. Cardiovasc. Diabetol. 20(1), 144 (2021).","journal-title":"Cardiovasc. Diabetol."},{"issue":"11","key":"59298_CR37","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.3390\/ijms25115640","volume":"25","author":"P Portincasa","year":"2024","unstructured":"Portincasa, P. et al. Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options. Int. J Mol. Sci. 25(11), 5640 (2024).","journal-title":"Int. J Mol. Sci."},{"issue":"12","key":"59298_CR38","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s11883-024-01241-3","volume":"26","author":"A d\u2019Aiello","year":"2024","unstructured":"d\u2019Aiello, A. et al. Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment. Curr. Atheroscler. Rep. 26(12), 707\u2013719 (2024).","journal-title":"Curr. Atheroscler. Rep."},{"key":"59298_CR39","doi-asserted-by":"crossref","unstructured":"Pieter, B. W., Luisa, V., Maja, T., J\u00f6rn, S., Foteini, A., Sonja B, et al. Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management\u2606=. JHEP Reports. 101798 (2026).","DOI":"10.1016\/j.jhepr.2026.101798"},{"issue":"11","key":"59298_CR40","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3390\/life15111682","volume":"15","author":"C Stasi","year":"2025","unstructured":"Stasi, C. & Mega, A. Improvement of Liver Fibrosis in Patients with MASLD Undergoing Pioglitazone Treatment: An Update. Life. 15(11), 1682 (2025).","journal-title":"Life."},{"key":"59298_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116723","volume":"277","author":"R Amorim","year":"2024","unstructured":"Amorim, R. et al. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities. Eur. J. Med. Chem. 277, 116723 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"59298_CR42","doi-asserted-by":"publisher","first-page":"1393333","DOI":"10.3389\/fphar.2024.1393333","volume":"15","author":"Q Cheng","year":"2024","unstructured":"Cheng, Q. et al. Research trends in lipid-lowering therapies for coronary heart disease combined with hyperlipidemia: a bibliometric study and visual analysis. Front. Pharmacol. 15, 1393333 (2024).","journal-title":"Front. Pharmacol."},{"issue":"1","key":"59298_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2478\/enr-2021-0002","volume":"55","author":"II Bilous","year":"2021","unstructured":"Bilous, I. I., Pavlovych, L. L. & Kamyshnyi, A. M. Primary hypothyroidism and autoimmune thyroiditis alter the transcriptional activity of genes regulating neurogenesis in the blood of patients. Endocr. Regul. 55(1), 5\u201315 (2021).","journal-title":"Endocr. Regul."},{"issue":"2","key":"59298_CR44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2478\/enr-2020-0013","volume":"54","author":"II Bilous","year":"2020","unstructured":"Bilous, I. I., Korda, M. M., Krynytska, I. Y. & Kamyshnyi, A. M. Nerve impulse transmission pathway-focused genes expression analysis in patients with primary hypothyroidism and autoimmune thyroiditis. Endocr. Regul. 54(2), 109\u2013118 (2020).","journal-title":"Endocr. Regul."},{"issue":"4","key":"59298_CR45","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jhep.2024.05.008","volume":"81","author":"S Gawrieh","year":"2024","unstructured":"Gawrieh, S. et al. Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD. J. Hepatol. 81(4), 600\u2013608 (2024).","journal-title":"J. Hepatol."},{"issue":"10","key":"59298_CR46","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/hep4.1753","volume":"5","author":"M Merkel","year":"2021","unstructured":"Merkel, M. et al. Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant. Hepatol. Commun. 5(10), 1755\u20131766 (2021).","journal-title":"Hepatol. Commun."},{"issue":"11","key":"59298_CR47","first-page":"2646","volume":"12","author":"A Lazar","year":"2022","unstructured":"Lazar, A. et al. Dynamic Changes in Liver Stiffness in Patients with Chronic Hepatitis B Undergoing Antiviral Therapy. Diagn. (Basel, Switzerland). 12(11), 2646 (2022).","journal-title":"Diagn. (Basel, Switzerland)."},{"key":"59298_CR48","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jare.2025.05.028","volume":"80","author":"Y Zhang","year":"2026","unstructured":"Zhang, Y. et al. Mechanical mechanics-reclaiming a new battlefield for chronic liver disease. J. Adv. Res. 80, 871\u2013891 (2026).","journal-title":"J. Adv. Res."},{"issue":"3","key":"59298_CR49","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/diagnostics15030303","volume":"15","author":"D Kavvadas","year":"2025","unstructured":"Kavvadas, D. et al. Shear Wave Elastography for Carotid Artery Stiffness: Ready for Prime Time?. Diagnostics. 15(3), 303 (2025).","journal-title":"Diagnostics."},{"issue":"1","key":"59298_CR50","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1186\/s12882-025-04612-3","volume":"26","author":"HM Ibrahim","year":"2025","unstructured":"Ibrahim, H. M., Ali, S. A., Ramzy, T. A., Elsaid, N. H. & Shaker, A. M. Role of serum periostin level as profibrotic marker in conjunction with renal resistivity index and shear wave elastography in predicting renal fibrosis in diabetic nephropathy. BMC Nephrol. 26(1), 682 (2025).","journal-title":"BMC Nephrol."},{"key":"59298_CR51","doi-asserted-by":"crossref","unstructured":"Bilous, I., Pavlovych, L., Krynytska, I., Marushchak, M., Kamyshnyi, O. Apoptosis and Cell Cycle Pathway-Focused Genes Expression Analysis in Patients with Different Forms of Thyroid Pathology. Open Access Macedonian Journal of Medical Sciences. Vol. 8 No. B (2020): B - Clinical Sciences:784\u201392 (2020).","DOI":"10.3889\/oamjms.2020.4760"},{"issue":"12","key":"59298_CR52","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/17512433.2025.2600410","volume":"18","author":"X Fang","year":"2025","unstructured":"Fang, X. et al. Efficacy and safety of statins for nonalcoholic\/metabolic dysfunction-associated fatty liver diseases: a systematic review and meta-analysis. Expert. Rev. Clin. Pharmacol. 18(12), 1095\u20131106 (2025).","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"59298_CR53","doi-asserted-by":"publisher","first-page":"117955221878750","DOI":"10.1177\/1179552218787502","volume":"11","author":"MA Sigler","year":"2018","unstructured":"Sigler, M. A., Congdon, L. & Edwards, K. L. An Evidence-Based Review of Statin Use in Patients With Nonalcoholic Fatty Liver Disease. Clin. Med. Insights Gastroenterol. 11, 1179552218787502 (2018).","journal-title":"Clin. Med. Insights Gastroenterol."},{"key":"59298_CR54","doi-asserted-by":"crossref","unstructured":"Ayada, I., van Kleef, L. A., Zhang, H., Liu, K., Li, P., Abozaid, Y. J, et al. Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study. EBioMedicine. 87, (2023).","DOI":"10.1016\/j.ebiom.2022.104392"},{"issue":"19","key":"59298_CR55","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.3390\/nu16193349","volume":"16","author":"I Halabitska","year":"2024","unstructured":"Halabitska, I., Oksenych, V. & Kamyshnyi, O. Exploring the Efficacy of Alpha-Lipoic Acid in Comorbid Osteoarthritis and Type 2 Diabetes Mellitus. Nutrients 16(19), 3349 (2024).","journal-title":"Nutrients"},{"issue":"2","key":"59298_CR56","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/ehjcvp\/pvae095","volume":"11","author":"L Fr\u00fchwald","year":"2025","unstructured":"Fr\u00fchwald, L. et al. Management of dyslipidaemia in patients with comorbidities-facing the challenge. European Heart J. Cardiovasc. Pharmacother. 11(2), 164\u2013173 (2025).","journal-title":"European Heart J. Cardiovasc. Pharmacother."},{"issue":"2","key":"59298_CR57","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s12072-024-10774-3","volume":"19","author":"M Eslam","year":"2025","unstructured":"Eslam, M. et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol. Int. 19(2), 261\u2013301 (2025).","journal-title":"Hepatol. Int."},{"key":"59298_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106679","volume":"189","author":"M Rizzo","year":"2023","unstructured":"Rizzo, M. et al. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP). Pharmacol. Res. 189, 106679 (2023).","journal-title":"Pharmacol. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59298-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59298-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59298-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:05:47Z","timestamp":1790643947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59298-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["59298"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-59298-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"21 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (as amended) and national regulations. The research protocol was approved by the Bioethics Commission of I. Horbachevsky Ternopil National Medical University (Protocol No. 81 dated April 3, 2025). Written informed consent was obtained from all participants prior to inclusion in the study.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"30158"}}